Axel Benner

Research Topics

• Time to event data analysis
• Statistics for high-dimensional covariate space
• Clinical statistics

Education

Diploma in Statistics, University of Dortmund 1978-1986

Other Experience and Professional Memberships

• International Biometric Society (IBS)
• International Society for Clinical Biostatistics (ISCB)
• American Statistical Association (ASA)

 - Reviewer for Journal of Clinical Oncology, Statistics in Medicine, Biometrical Journal, Computational Statistics & Data Analysis, Bioinformatics and others
 - Member of the "High-dimensional data" topic group of the STRATOS initiative
 - Faculty member of the EHA Clinical Research Training in Hematology (CRTH) program
 - Member of the Extended Board of the German Speaking Myeloma Multicenter Group (GMMG)
 - Lead Biometrician of the German AML Study Group (AMLSG) and the German Speaking Myeloma Multicenter Group (GMMG)

Publication list (10 most relevant; last 5 years)

1. Edelmann D, Welchowski T, Benner A. A consistent version of distance covariance for right-censored survival data and its application in hypothesis testing. Biometrics 2021, 1-13.

2. De Bin R, Boulesteix A-L, Benner A, Becker N, Sauerbrei W. Combining clinical and molecular data in regression prediction models: insights from a simulation study. Briefings in Bioinformatics 2020; 21: 1904-1919.

3. Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar S, Klisovic RB, Wei AH, Sierra J, Sanz M, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood 2020;135(5):371-380.

4. Edelmann D, Hummel M, Hielscher T, Saadati M, Benner A. Marginal variable screening for survival endpoints. Biometrical Journal 2020; 62: 610-626.

5. Edelmann D, Ohneberg K, Becker N, Benner A, Schumacher M. Which patients to sample in clinical cohort studies when the number of events is high and measurement of additional markers is constrained by limited resources. Cancer Medicine 2020; 9: 7398-7406.

6. Kimmich CR, Terzer T, Benner A, Dittrich T, Veelken K, Carpinteiro A, Hansen T, Goldschmidt H, Seckinger A, Hose D, Jauch A, Wörner S, Beimler J, Müller-Tidow C, Hegenbart U, Schönland SO. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood 2020; 135: 1517-1530.

7. Krzykalla J, Benner A, Kopp-Schneider A. Exploratory identification of predictive biomarkers in randomized trials with normal endpoints. Statistics in Medicine, 39: 923-939, 2020.

8. Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncology 2019; 20: 1576-1586.

9. Habermehl C, Benner A, Kopp‐Schneider A. Addressing small sample size bias in multiple‐biomarker trials: Inclusion of biomarker‐negative patients and Firth correction. Biometrical Journal 2018; 60: 275-287.

10. Saadati M, Beyersmann J, Kopp-Schneider A, Benner A. Prediction accuracy and variable selection for penalized cause-specific hazards models. Biometrical Journal 2018; 60: 288-306.